Meeting
2022 ASCO Annual Meeting
Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
Authors
Lauren Reed-Guy
Hospital of the University of Pennsylvania, Philadelphia, PA
Lauren Reed-Guy , Arati Suvas Desai , Richard Edmund Phillips , Desiree Croteau , Meghan O'Neill , Karen Albright , Steven Brem , Donald M. O'Rourke , Nduka Amankulor , Stephen Joseph Bagley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2015)
DOI
10.1200/JCO.2022.40.16_suppl.2015
Abstract #
2015
Poster Bd #
353
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
First Author: Deborah Schrag
Poster
2021 Genitourinary Cancers Symposium
A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).
First Author: Ulyana Dashkevych
Poster
2021 Genitourinary Cancers Symposium
Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
First Author: Akram Mesleh Shayeb
Poster
2022 ASCO Annual Meeting
Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis.
First Author: Irbaz Bin Riaz